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Abstract
Background: Electroacupuncture (EA) intervention can relieve a variety of pain; however, optimal EA protocols have
not been clearly determined. In addition, although central mitogen-activated protein kinase kinase (MEK) signaling has
been shown to be involved in the antinociceptive effect of acupuncture stimulation, its characteristics at different
time-points of EA intervention have not been fully elucidated. Therefore, the present study investigated the
relationship between the effects of different numbers of EA intervention sessions and the activation of MEK1 in
the hippocampus and hypothalamus in a rat model of neuropathic pain.
Methods: After ligation of the left sciatic nerve, which induces chronic constriction injury (CCI), the acupoints Zusanli
(ST36) and Yanglingquan (GB34) were applied. The thermal withdrawal latency of the hind paw was used to evaluate
the effect of EA on pain thresholds. Intra-hippocampus microinjection of PD98059, a MEK inhibitor, was performed to
validate the involvement of MEK in EA analgesia. The hippocampus and hypothalamus were harvested to examine the
phosphorylation levels of MEK (pMEK) by western blotting.
Results: In CCI rats, the thermal pain threshold of the affected hind paw decreased significantly relative to the control.
Following subsequent daily EA interventions, CCI-induced ipsilateral hyperalgesia was markedly improved from day 4
and the analgesic effect of EA lasted 3 days after cessation of EA. Four sessions of EA markedly suppressed CCI-induced
decrease of hippocampal pMEK1 (normalized to the total MEK level). In contrast, successive sessions of EA intervention
gradually down-regulated the CCI-induced up-regulation of hypothalamic pMEK1 along with the increase numbers of
EA intervention. However, EA did not exert the same analgesic effect after microinjection of PD98059 into the
contralateral hippocampus during the first 3 days of EA intervention.
Conclusions: EA intervention can induce time-dependent cumulative analgesia in neuropathic pain rats after 4
successive sessions of daily EA intervention, which is at least in part related to the activation of hippocampal MEK1.
Keywords: Acupuncture analgesia, Neuropathic pain, Cumulative effect, Hippocampus, Mitogen-activated protein
kinase kinase 1
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Background
Neuropathic pain is a refractory chronic pain syndrome
with a complicated mechanism that currently has no
effective therapy. Acupuncture therapy, a method of
traditional Chinese medicine, has received worldwide
attention as a strategy to relieve pain [1–3]. Clinical
practice demonstrates that multiple sessions of acu-
puncture treatment (not a single session) may induce
an obvious analgesic effect [4–6]. However, the number
of acupuncture treatment sessions required for effective
pain relief is unclear.
Several lines of evidence demonstrated that the
short-term effect of a single session of acupuncture
stimulation differs from the cumulative effect of mul-
tiple sessions of acupuncture stimulation, which may
depend on the differential modulation of immunologic
factors and neurotrophic signaling molecules [7–9].
Our previous study showed that the cumulative anal-
gesic effect of repeated electroacupuncture (EA) inter-
vention in neuropathic pain rats is closely associated
with its regulatory effects on natural killer cells as well
as some splenic and plasma cytokines [10]. Some find-
ings suggested that multiple sessions of EA induced
up-regulation of angiotensin I and II and the δ-opioid
receptor in cerebral ischemia rats [11, 12]. However,
the central regulation mechanism of the cumulative
analgesic effect of multiple sessions of EA intervention
remains unknown, particularly under chronic pain
conditions. Answering these questions will provide
new evidence and shed new light on the targets of acu-
puncture intervention.
There was evidence that acupuncture stimulation of
remote acupoints induced responses in various brain
regions to exert its function [13], and many nuclei of
the limbic system and brainstem have been experimen-
tally confirmed to mediate acupuncture information
[14]. Our previous study demonstrated that in chronic
constriction injury (CCI)-induced neuropathic pain
rats, the cumulative analgesic effect of repeated EA
stimulation of Zusanli (ST36)-Yanglingquan (GB34) is
closely associated with its effects in upregulating the
decreased hippocampal synaptophysin immunoreactiv-
ity and improving synaptic plasticity in the hippocam-
pus [15]. Blocking neural transmission along the major
afferent or efferent hippocampal pathways reduced
pain behaviors [16, 17]. These findings may support
the notion that hippocampal formation plays an im-
portant role in both pain and EA perception. Our
initial work showed that the hippocampus participated
in the cumulative analgesic effect of multiple sessions
of EA intervention, and many molecules in this brain
region were implicated in this process [18]. Among
them, mitogen-activated protein kinase kinase 1 (MEK1)
signaling has warranted special attention.
MEK1 is crucial in hippocampal-dependent learning,
memory, and synaptic plasticity [19]. A close relation-
ship has been documented between neuropathic pain
and activation of MEK1. For example, MEK1 in dorsal
horn neurons of the spinal cord and in the amygdala
contributed to pain [20]. In our previous study, proteins
differentially expressed in the hippocampus and hypo-
thalamus were identified using two-dimensional gel
electrophoresis and matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry. We found
that after CCI, MEK1 was down-regulated in the hippo-
campus and up-regulated in the hypothalamus. How-
ever, following 12 sessions of EA intervention, MEK1 in
both regions recovered to normal levels [18, 21]. We
extended that work in the present study to clarify the
differential effects of multiple and single EA interven-
tion sessions in CCI rats. We examined the changes of
MEK1 activation in the hippocampus and hypothal-
amus after different EA intervention sessions. In
addition, we assessed the involvement of MEK1 in the
cumulative analgesic effect of multiple sessions of EA
intervention by intra-hippocampal injection of a MEK1
inhibitor in neuropathic pain rats.
Methods
Animals
Male Wistar rats (240–300 g) were obtained from the
Experimental Animal Center of the Peking Union
Medical College (Beijing, China) and housed within the
animal care facilities in the Institute of Acupuncture
and Moxibustion, China Academy of Chinese Medical
Sciences. Food and water were available ad libitum. The
animals were allowed to adapt to the experimental con-
ditions in the laboratory for at least 2 h before pain
testing. All experimental procedures were approved by
the Institute of Acupuncture and Moxibustion of China
Academy of Chinese Medical Sciences and were identi-
cal to those recommended in the Guidelines for La-
boratory Animal Care and Use from the Chinese
Ministry of Science and Technology (2006). Efforts
were made to minimize the number and suffering of
the animals used.
Experimental design
The study consisted of the following two experiments:
Experiment 1 was designed to examine the effects of
EA on MEK1 activation. For this experiment, rats with
CCI were randomized into eight groups (n = 10 in each
group): sham operation control (CON), CCI model, and
CCI plus an increasing number of daily EA treatment
(EA2d, EA4d, EA6d, EA8d, EA10d, and EA12d);
Experiment 2 was designed to validate the effects of
MEK1 depletion on the cumulative effects of EA inter-
vention. Rats that received CCI and implantation of
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guide cannulas in the contralateral hippocampus were
divided into four groups and treated with either a
microinjection of dimethyl sulfoxide (DMSO for con-
trol; two groups, CCI + DMSO, CCI + DMSO + EA) or
PD98059 (a MEK1 inhibitor, two groups, CCI +
PD98059, CCI + PD98059 + EA). To observe the differ-
ent effects of PD98059 at different stages of EA inter-
vention, a 3-day cycle hippocampal microinjection was
given on the first 3 days of EA or given on day 8, 9, and
10 of EA separately (n = 10 in each group). To examine
the effect of a combination of microinjection and EA,
rats received a microinjection 4.5 h prior to EA stimu-
lation. To clarify the effect of PD98059, a CON +
PD98059 group was added (n = 10). Randomization
scheme was created using the standard = RAND()
function in Microsoft Excel.
CCI pain model and behavioral tests
The CCI model was established by unilaterally ligating
the sciatic nerve, as previously reported [22]. Briefly,
under anesthesia (25% urethane plus 1.5% chloralose,
0.4 mL/100 g body weight) and using routine sterile
procedures, the left sciatic nerve was exposed at the
mid-thigh level by blunt dissection through the biceps
femoris. Four constrictive ligatures (4–0 non-absorbable
suture) equally spaced by approximately 1 mm were tied
around the nerve at the distal end close to the bifur-
cation site. The ligatures were tightened until a moder-
ate muscular contraction of the leg was observed. For
the CON group, the rats underwent the same procedure
but without nerve ligation.
One day before ligation, 10 days after ligation, and
everyday within 0.5 h before EA stimulation, the paw
withdrawal latencies (PWL, i.e., thermal pain threshold)
of both hind paws were determined using a 37370
Algesia Detector (Ugo, Italy). A radiant heat source was
focused on the plantar surface of a hind paw, and a
light intensity was preset to obtain a baseline latency of
approximately 25 s. Each rat underwent three trials
with a 5-min interval, and the mean value of three trials
was used as the PWL.
Electroacupuncture
According to traditional Chinese medicine theory,
Zusanli (ST36) and Yanglingquan (GB34) are considered
the most effective acupoints for treating low back pain
and are commonly used to study the acupuncture effects
on various physiological regulatory and control systems
in modern scientific research. ST36 is located 5 mm be-
neath the capitulum fibulae and lateral posterior to the
knee joint, and GB34 is approximately 5 mm superior-
lateral to ST36 [18]. In the present study, the animals in
the EA group were treated with bilateral ST36 and
GB34. The acupoints were punctured with stainless steel
filiform needles (diameter 0.35 mm, length 40 mm,
Huatuo; Suzhou Medical Appliance Manufactory,
Jiangsu, China) to a depth of approximately 2–3 mm,
and stimulated electrically for 30 min using a Han’s EA
Stimulator (LH202; Neuroscience Research Center,
Peking University, Beijing, China). The EA stimulation
parameters were 1 mA and 2 and 15 Hz alternating
frequencies (automatically shifting between 2 Hz and
15 Hz stimulation for 3 s each), respectively. EA stimu-
lation started from the 10th day after CCI. During EA
stimulation, the animals were awake and constrained
with a special cloth bag. As neither the ipsilateral nor
the contralateral PWLs were influenced by the repeated
constraining process in CCI rats, the non-EA groups
(CCI and CON groups) underwent the same constrain-
ing procedure, but without EA stimulation.
Microinjection procedure
Under anesthesia with urethane and chloralose, after
CCI operation, two 6-mm-long stainless steel guide can-
nulas (Small Parts Inc., Hialeah, Florida, USA) were
stereotaxically implanted into the contralateral hippo-
campus (3.3–3.6 mm posterior to the bregma, 2.4–
2.7 mm lateral to the midline, and 3.0–3.5 mm below
the cortical surface) based on the coordinates in the
atlas completed by Paxinos and Watson [23], with the
tip retained about 2 mm above the dura. The guide can-
nulas were anchored to the cranium with dental cement.
The animals were allowed to recover for 10 days. The
guide cannulas were plugged with a stainless steel stylet,
which was removed before drug administration.
PD98059 (Abcam, New Territories, HK) dissolved in
5% (v/v) DMSO (Abcam) was administered to the
PD98059 groups. The DMSO groups received the same
volume of 5% (v/v) DMSO as control. Drugs were admin-
istered into the hippocampus through the guide cannulas
using an injection needle (gauge 27) connected by poly-
ethylene tubing to a 10-μL Hamilton microsyringe while
the rats were anesthetized under isoflurane anesthesia.
PD98059 (10 μg/10 μL) or DMSO (5% (v/v)/10 μL) was
injected over 3 min, 4 h prior to behavioral testing.
At the end of each set of experiments, the microinjec-
tion sites of one rat in each group were marked with
2 μL of a saturated solution of Pontamine sky blue
(Sigma Chemical Co. St. Louis, MO, USA) to determine
the distribution of the injection. After fixation with 10%
(v/v) formalin, the brain was sectioned and counter-
stained with cresyl violet. The microinjection sites were
histologically verified and plotted based on the Paxinos
and Watson stereotaxic atlas coordinates. A representa-
tive microinjection site is shown in Fig. 1. For all animals
examined, the cannula tips were located just in the tar-
get region, and the injection tracks were limited to the
CA region or dentate gyrus of the hippocampus.
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Tissue harvest and western blot analysis
After termination of the behavioral test, rats in each
group were deeply anesthetized and killed by decapita-
tion. The right and left hypothalamus and hippocampi
were removed rapidly on an ice plate and then washed
with normal saline. Tissue extracts were obtained using
mechanical tissue disruption in RIPA lysis buffer with 1×
Complete Anti-Protease Cocktail (Roche, Indianapolis,
IN, USA), 1 mM PMSF, and incubation for 10 min at
4 °C. Lysates were cleared by centrifugation at 10,000 g
for 10 min at 4 °C. Total protein (30 μg) was loaded
onto 10% (w/v) gels for sodium dodecyl sulfate poly-
acrylamide gel electrophoresis and transferred onto
polyvinylidene membranes (Millipore, Billerica, MA,
USA) for western blot analysis. Membranes were then
incubated with primary antibodies (anti-MEK1, 1:1000;
anti-phospho-MEK1, 1:800; anti-GAPDH, 1:500; Cell
Signaling, Beverly, MA, USA) overnight at 4 °C with 2%
(w/v) bovine serum albumin in PBST. The membranes
were then washed three times with PBST (10 min each
time), incubated with the appropriate horseradish
peroxidase-conjugated secondary antibody for 2 h at
room temperature, followed by three washes with
PBST. Immunoreactive bands were then revealed by
enhanced chemiluminescence (Amersham Biosciences
UK Limited, Buckinghamshire, England) using standard
x-ray film (Eastern Kodak Co., Rochester, NY, USA).
The relative intensities of the detected protein bands
were analyzed with a Personal Densitometer SI (Amer-
sham Biosciences) linked to ImageQuant 5.2 software
(Amersham Biosciences).
Statistical analysis
SPSS 17.0 software was used to perform the statistical
analysis. The results are expressed as the mean ± SD.
PWLs were analyzed using two-way repeated measures
analysis of variance (ANOVA) with one between-subject
factor (EA intervention) and one within-subject factor
(time) followed by the least significant difference (LSD)
analysis. Western blot data were analyzed using one-way
analysis of variance and the LSD test was performed
to compare the differences between two groups. All
P values were derived from two-sided tests, and P < 0.05
was considered statistically significant.
Results
Effects of EA treatment on pain threshold
Baseline measures of PWL to radiant heat stimulation
on both hind paws did not differ among the CON, EA,
and CCI groups. Ten days after surgery, strong thermal
hyperalgesia developed in the ipsilateral hind paw. Two-
way repeated measures ANOVA showed no significant
interaction between EA intervention and time-points
(P = 0.083) and a significant difference among the
CON, EA and CCI groups (P < 0.01). Following four
successive daily EA interventions, CCI-induced ipsilat-
eral hyperalgesia was markedly suppressed and the
PWL displayed a time-dependent increase from the 4th
day onwards (Fig. 2a). Furthermore, after four succes-
sive sessions of EA intervention, the analgesic effect of
EA lasted at least 3 days after cessation of EA. How-
ever, after 2 successive sessions of EA intervention, the
lasting effect was not observed (Fig. 2c). PWL in the
contralateral hind paw was not different among the
three groups and remained stable during the interven-
tion process (Fig. 2b).
Effect of EA treatment sessions on pMEK1 protein
To examine whether MEK1 is activated in the hippo-
campus and hypothalamus after CCI and EA, we per-
formed a western blot analysis with antibodies targeting
the total MEK1 expression and the dually phosphory-
lated MEK1 (pMEK1, Ser217/221) because phosphoryl-
ation at Ser-217 and Ser-221 positively regulates MEK1
activity. In hippocampal tissue contralateral to the CCI
limb, we observed a reduction of pMEK1 in rats with
CCI compared with the sham operation control group.
This reduction was significantly reversed from day 2 to 4
of EA treatment, and MEK1 activation in rats with EA
was higher than that in the CON group animals (P <
0.01). After 6 days' EA stimulation, the contralateral
hippocampal pMEK1 was significantly decreased and
nearly returned to the control level after 12 sessions of
EA (Fig. 3a). After normalizing pMEK1 levels to total
MEK1 levels (pMEK1 versus MEK1), the same results
were obtained as above (Fig. 3d). No significant
changes in pMEK1 expression were noted in the ipsi-
lateral hippocampus throughout the time course of EA
(Fig. 3a) and no significant changes were found in total
MEK1 expression levels (Fig. 3c).
Fig. 1 Representative photomicrograph of the location of the
injection site in the rat hippocampus
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Contralateral hypothalamic pMEK1 protein expression
was considerably increased following CCI and gradually
decreased with an increase of EA intervention sessions
and finally returned to the control level after 12 EA ses-
sions (Fig. 3b and d). Similar results to the ipsilateral
hippocampus were seen, and no changes in pMEK1 ex-
pression were found in the hypothalamus ipsilateral to
the affected limb following CCI and EA intervention
(Fig. 3b).
Effect of EA combined with PD98059 on pain threshold
To detect the different role of MEK1 at different stages
of EA intervention, the selective MEK1 inhibitor
PD98059 was injected into the contralateral hippocam-
pus on the first 3 days or on day 8, 9, and 10 of EA
treatment separately. For rats in the CCI group, after
PD98059 administration on day 1, 2, and 3 or on day 8,
9, and 10, the thermal pain thresholds of the affected
hind paw showed no apparent changes compared with
those following administration of DMSO (Fig. 4a, b).
After PD98059 administration in rats from the EA inter-
vention group on day 1, 2, and 3, the thermal pain
thresholds of the affected hind paw showed no apparent
changes compared with those of administration of
DMSO. However, after completion of the first 3-days’
administration, the PWL was increased continually in
the DMSO group while the PWL in the PD98059 group
showed no apparent increase during the following EA
days. On the 5th day of EA intervention, the PWL in the
DMSO group was significantly higher than that in the
PD98059 group (P = 0.036, Fig. 4a). After administration
of PD98059 on day 8, 9, and 10 of EA interventions,
Fig. 2 Effect of EA stimulation on PWL in CCI rats. a ipsilateral and b contralateral paw. c The lasting effect of the number of EA interventions
(2 or 4 days of treatment) on PWL. The double-slash indicates EA intervention was discontinued. Data are presented as the mean ± SD; n = 10 in
each group. #P < 0.05 vs. CON group, *P < 0.05 vs. CCI group, ☆P < 0.05 vs. EA2d group
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Fig. 3 Effect of EA stimulation on pMEK1 and MEK1 expression in CCI rats. a The level of pMEK1 in the hippocampus b The level of pMEK1 in the
hypothalamus c The expression of MEK1 in the hippocampus and hypothalamus contralateral to the injured sciatic nerve d The fold change for
the gray scale ratio of pMEK normalized to the total MEK. Data are presented as the mean ± SD; n = 10 in each group. #P < 0.05 vs. CON group, *P
< 0.05 vs. CCI group
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the PWLs were slightly increased compared with those
in rats of the DMSO group. However, no significant dif-
ference was observed (Fig. 4b).
Effect of EA combined with PD98059 on the pMEK1 protein
To determine the effect of PD98059 microinjections on
EA functions in regulating MEK expression, we exam-
ined the levels of pMEK1 in the contralateral hippo-
campus and hypothalamus after completion of each
cycle of the 3-day PD98059 injection, namely on the 3rd
and 10th day of EA intervention, as well as after 2 days’
rest (i.e., on the 5th and 12th day of EA treatment).
After completion of PD98059 injection, on day 3 and
10 of EA intervention, the pMEK1 in the contralateral
hippocampus were considerably down-regulated in the
CCI+ PD98059 and CCI + EA + PD98059 groups in
comparison with those of the corresponding DMSO
control groups (P < 0.05, Fig. 5a). After 2 days’ rest, on
day 12, the decreased levels of hipppocampal pMEK1
protein in the two PD98059 administration groups (i.e.,
CCI+ PD98059 and CCI + EA + PD98059) were com-
parable tothose of their corresponding DMSO control
groups (P > 0.05). However, on day 5, the pMEK1 in the
CCI + EA + PD98059 group in the contralateral hippo-
campus remained lower than that in the EA + DMSO
group.
After hippocampal microinjection of MEK1 antagonist
PD98059, there were no apparent differences in the
levels of hypothalamic pMEK1 protein between the
PD98059 groups and their corresponding DMSO control
groups on days 3, 10, and 12 (P > 0.05,). However, after
hippocampal microinjection of PD98059, the decreased
level of pMEK1 in the contralateral hypothalamus in-
duced by 5 days' EA treatment was no longer observed,
being significantly higher than that in the EA + DMSO
group (P = 0.041, Fig. 5b).
Discussion
Although it has been reported that EA intervention ef-
fectively alleviated pain, the optimal EA treatment proto-
col remains unclear. In this study, no significant changes
were observed in the PWL during the first three sessions
of EA intervention, meaning no remarkable pain relief at
that time, but a marked increase of the pain threshold
was observed after four sessions of EA intervention, pre-
senting a time-dependent pain relief thereafter. This was
consistent with our previous study [10]. We also deter-
mined the duration of the post-effect of EA treatment.
Our results indicated that after four successive sessions
of EA, even when the EA treatment was discontinued,
the increased pain threshold could last for 3 days.
However, after only two sessions of EA intervention,
no marked post-effect was found. Hence, these results
suggest an apparent cumulative antinociceptive effect
of four successive sessions of EA treatment in chronic
neuropathic pain rats.
Pain is characterized as a multidimensional experience,
involving nociception, emotional, and cognitive aspects.
The hippocampus, a major component of the limbic
system, has been shown to contribute to pain-related
memory and emotional disorders [24, 25]. Recent find-
ings suggested an association between chronic pain and
alterations in the hippocampus [26, 27]. However, the
potential mediators associated with these alterations
have not been determined. Several lines of evidence
demonstrated that noxious stimulation induced an alter-
ation in hippocampal intracellular signaling cascades,
and resulted in synaptic transmission modifications af-
fecting neuronal excitation in the hippocampus [27–29].
These modifications lead to amplification of pain signal-
ing, that is thought to be critical for the recovery and
survival of an organism following injury. Among them,
MEK1 signaling has been shown to be implicated in
Fig. 4 Effect of intra-hippocampal microinjection of the selective
MEK1 inhibitor PD98059 at different time-points on PWL in a rat
model of neuropathic pain. a Microinjection was given on the first
3 days of EA, b microinjection was given from the 8th day of EA.
The black arrowheads indicate the day of PD98059 or DMSO
administration. Data are presented as the mean ± SD; n = 10 in
each group. #P < 0.05 vs. CCI+ PD98059 + EA group
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hippocampus-dependent memory formation. Impaired
memory, a prominent complaint of patients with chronic
pain, substantially contributes to pain-related disability
[30, 31]. Based on our initial results that hippocampal
MEK1 was altered differently after CCI and EA interven-
tion, here, we tested whether hippocampal MEK1 was
involved in the cumulative antinociceptive effect of EA
intervention. We found that the number of EA treat-
ment sessions, fewer than four sessions versus more
than four sessions, was closely associated with different
patterns of pMEK1 in the hippocampus. In the first four
EA intervention sessions, hippocampal pERK1 was signifi-
cantly increased in comparison to the CCI and control
animals. After the cumulative analgesic effect of EA was
present, hippocampal pMEK1 levels decreased gradually.
These data suggest that MEK1 is activated in the hippo-
campus contralateral to the nerve injury side following
four times of EA intervention, and this increase in MEK1
activity may initiate a cumulative effect of EA treatment.
Previously reported gene screening results suggest that
the discrepancy between the effects of multiple and single
EA treatments on brain ischemia/reperfusion are possibly
caused by their differential modulation on gene expres-
sion, such as brain-derived neurotrophic factor and signal
transducer-related genes [4]. This proposal is consistent
with our data. In addition, after suppressing MEK1 with
its specific antagonist in the early stage of the successive
EA intervention, the time-dependent decrease of PWL
following four successive sessions of EA did not appear as
expected, indicating that MEK1 may contribute to the ini-
tiation of the cumulative acupuncture analgesia. After the
completion of each cycle of the 3-day PD98059 injections,
namely on the 3rd and 10th day of EA intervention, the
expression levels of pMEK1 in the contralateral hippo-
campus were considerably down-regulated. In the first
four EA intervention sessions, no obvious lasting effect of
EA was shown, so the effect of pMEK1 decreasing with
PWL was not obvious during this period. But with a
marked increase in the pain threshold after four sessions
of EA intervention, the effect of pMEK1 decreasing with
EA was obvious, appearing on day 5. However, we do
not interpret our results to mean that PD98059 needs
such a long time to play a role. Rather, the first 3-day
PD98059 injections disrupted the cumulative EA treat-
ment effect after four EA intervention sessions. These
results indicate the different role of MEK1 at different
EA intervention sessions. That is, suppression of MEK1
at the early stage of EA intervention may decrease the
EA effect, whereas after multiple EA sessions, the effect
of EA interventions may become pMEK1-independent.
Some studies have demonstrated that EA intervention
can modulate the function of interneurons in the hippo-
campus and enhance long-term potentiation in the rat
[32]. At the neural level, pain is expected to lead to
Fig. 5 Effect of the MEK1 inhibitor PD98059 on a hippocampal and b hypothalamic pMEK1 in a rat model of neuropathic pain. Data are
presented as the mean ± SD; n = 10 in each group. * P < 0.05
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stronger modulations in memory-related brain regions
of the medial temporal lobe, such as the hippocampus,
during encoding [33, 34]. These findings may give rise to
the idea that a “pain memory” is encoded within the ner-
vous system [35]. In daily life activities, humans and ani-
mals are constantly exposed to simultaneous inputs from
different sensory modalities. In this complex environment,
different stimuli commonly compete for limited process-
ing resources [36]. Under such conditions, MEK1 signal-
ing shows differential expression patterns based on the
nociceptive stimulus. A study by Seo and colleagues
showed that in acute or transient pain, the kinases down-
stream of MEK1 were increased, and single-stimulus pain
upregulated hippocampal MEK signaling, which is critical
for long-term information storage as well as neuronal
adaptive responses [37]. However, with regard to chronic
pain, there is a marked decrease in phosphorylation and
gene expression of the components of MEK1 signaling
[26]. These results demonstrate that the hippocampus
processes pain-related information differently based on
the pain modality. The animal is thought to undergo some
important psychophysical aspects of pain, such as an en-
hanced response to a normally noxious stimulus and an
allodynia response to a normally innocuous stimulus dur-
ing CCI [38]. A single or few sessions of acupuncture
intervention may also be regarded as acute nociceptive
stimuli under CCI conditions and would compete with
CCI-induced pain processing, such as MEK1 signaling, to
inhibit chronic pain inducing. This may explain why in
the first four sessions of EA intervention, MEK1 activation
in rats with EA was higher than that in CCI animals. A
study showed that the cumulative effects in the process of
repeated acupuncture stimulation may be an interesting
characteristic of bimodal habituation [9]. In other words,
information induced by repeated EA stimulation may
form a type of habitual memory in the hippocampus.
Thus, it is feasible to think that the acupuncture memory
may compete with the pain memory. Our study showed
that a single EA stimulus induced upregulation of hippo-
campal pMEK1, which may be a major molecular mech-
anism for converting immediate EA-induced signaling
to repeated treatment-induced EA signaling. After several
sessions of EA treatment, with the neuronal adaptive re-
sponse and the formation of habitual memory, the acute-
specific effects of EA intervention may be gradually de-
creased, progressively decreasing the activation of MEK1
to normal levels. PWL is gradually increased after re-
peated EA treatment and returns to the normal level after
12 sessions of EA treatment. In parallel, pMEK is grad-
ually decreased to the control level after 12 sessions of EA
treatment. This suggests that activation of hippocampal
MEK1 is implicated in the effect of EA. On day 12, with
the increased number of EA sessions, the PWL and
MEK1 levels return to normal values. Because MEK1
signaling is necessary for cell survival, the reduction of
MEK1 signaling observed in the hippocampus of chronic
neuropathic pain animals may influence the reduction of
neurogenic cells and decrease the hippocampal volume
[26]. These unique hippocampal disruptions are specific
cellular correlation of the observed cognitive and emo-
tional problems seen both in animal models of chronic
pain and human patients with pain. Therefore, targeting
the reversal of these systematic changes in chronic pain
may provide an opportunity to permanently alleviate
chronic pain. This is further supported by the result of the
present study that the changed MEK1 activation induced
by repeated EA intervention contributed to the increase of
pain threshold in CCI rats. Therefore, further experiments
should be performed to explore the exact role of MEK1
activation and how MEK1 interacts with other molecules
following different sessions of EA.
After different EA treatment sessions, the alteration in
pMEK1 level in the hippocampus was different from that
in the hypothalamus. The pMEK1 in the hippocampus
contralateral to the nerve injury was markedly increased
after few EA treatment sessions, but decreased after
multiple EA sessions. In contrast, compared with the
CCI animals, hypothalamic pMEK1 level was decreased
after a single EA treatment and decreased further with
multiple EA sessions. These results indicate that the
MEK pathways in the hippocampus and hypothalamus
might contribute to the effects of EA treatments via
different transmission mechanisms. After suppression
of hippocampal MEK1 with PD98059, the decrease of
hypothalamic pMEK1 on days 3 and 5 of EA treatments
was no longer apparent, indicating that hippocampal
MEK1 may influence the phosphorylation levels of
hypothalamic MEK1. Although the mechanism mediating
the effect of hippocampal MEK1 on hypothalamic MEK1
was not determined in our study, a more thorough under-
standing of the mechanisms underlying these phenomena
will contribute to the refinement of therapeutic strategies
for a variety of pain conditions.
The main limit in our research is that there is no active
control group for EA (e.g., non-acupoint EA stimulation
or acupuncture needle insertions without electrical stimu-
lation). As procedures involving any kind of skin stimula-
tion have been considered not valid as insert controls to
acupuncture because they evoke activity in cutaneous
afferent nerves, resulting in alleviation of the affective
component of pain. Particularly, the present study does
not focus on the specificity of the analgesic effect of the
acupoint. In fact, the other two groups (CON group and
CCI group) underwent the same constraining procedure.
As neither the ipsilateral nor the contralateral PWLs were
influenced by the repeated constraining process in CCI
rats, this may allow us to reduce the number of control
animals used in future studies.
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Conclusion
Our data showed that four successive sessions of daily
EA treatment induced a time-dependent cumulative
analgesic effect, which persists for at least 3 days in a rat
model of neuropathic pain. This cumulative analgesic ef-
fect may depend on the activation of the MEK1 signaling
pathways in the contralateral hippocampus following
peripheral nerve injury.
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